PharmacoEconomics & Outcomes News 792, p16 - 2 Dec 2017 Lung involvement raises costs for systemic sclerosis patients Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) substantially increase healthcare costs and have poorer survival outcomes for patients with systemic sclerosis, according to a group of US- based researchers. The retrospective cohort analysis estimated all-cause healthcare use and costs (2014 values) from nationwide claims databases. Data were collected for patients with newly-diagnosed (incident) systemic sclerosis with or without ILD and/or PAH, who were continuously enrolled over a 5-year period. Of patients with continuous enrolment over a 5-year period, 1957 had incident systemic sclerosis, 219 had ILD-related disease and 108 had PAH-related disease. Average all-cause healthcare costs were substantially higher for patients with ILD- ($US191 107) and PAH- related disease ($254 425) over 5 years, compared with patients with non-lung-involved systemic sclerosis ($101 839). A similar pattern was seen for annual costs, where they ranged from $31 285 to $55 446 for the ILD group, $44 454 to $63 320 for the PAH group, and $18 513 to $23 268 for non-lung-involved disease. Median survival time was significantly shorter in the ILD and PAH groups (11.3, 8.8 vs 6.0 years, respectively; p < 0.001). "These data highlight that there remains an unmet need to identify more effective therapeutic strategies for both ILD and PAH", conclude the authors. * Funded by Genentech Inc and F. Hoffmann-La Roche. Fischer A, et al. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. The Journal of Rheumatology : 15 Nov 2017 803284966 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera